---
title: "Evoke Pharma | 8-K: FY2025 Q2 Revenue Misses Estimate at USD 3.752 M"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/253022867.md"
published_at: "2025-08-14T11:09:19.000Z"
---

# Evoke Pharma | 8-K: FY2025 Q2 Revenue Misses Estimate at USD 3.752 M

Revenue: As of FY2025 Q2, the actual value is USD 3.752 M, missing the estimate of USD 3.796 M.

EPS: As of FY2025 Q2, the actual value is USD -0.62.

### Segment Revenue

-   Net product sales for Q2 2025 were $3.8 million, a 47% increase from $2.6 million in Q2 2024.

### Operational Metrics

-   Net loss for Q2 2025 was - $1.6 million, or - $0.62 per share, compared to - $1.3 million, or - $0.93 per share, in Q2 2024.
-   Selling, general, and administrative expenses increased to $5.1 million in Q2 2025 from $3.7 million in Q2 2024, primarily due to higher profit-sharing with EVERSANA and increased professional fees.
-   Total operating expenses for Q2 2025 were $5.3 million, up from $3.8 million in Q2 2024.

### Cash Flow

-   Net cash used in operating activities for the six months ended June 30, 2025, was - $1.6 million, compared to - $3.4 million for the same period in 2024.
-   Cash and cash equivalents as of June 30, 2025, were $12.1 million.

### Unique Metrics

-   New prescribers increased by 20% year-over-year, indicating growing clinical adoption of GIMOTI.
-   Refill rates remained steady at approximately 70%.

### Outlook / Guidance

-   Evoke Pharma confirms its full-year 2025 net product sales guidance of approximately $16 million, representing up to a 60% increase over 2024. This guidance reflects trends in prescription growth, refill rates, and expanded pharmacy access, while considering external factors such as macroeconomic conditions and supply chain constraints.

### Related Stocks

- [EVOK.US - Evoke Pharma](https://longbridge.com/en/quote/EVOK.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Evoke (LON:EVOK) 的交易价格上涨了 14.6% - 你是否应该购买？ | Evoke plc (伦敦证券交易所代码：EVOK) 的股价在周五上涨了 14.6%，达到 30.20 便士，交易量较平均水平增加了 568%。分析师们的意见不一：Berenberg Bank 维持 “持有” 评级，目标价为 33 便士，而 | [Link](https://longbridge.com/en/news/273505316.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
